Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Down 5.4%

NASDAQ:TTNP opened at $4.42 on Tuesday. The stock has a 50 day moving average of $3.92 and a two-hundred day moving average of $3.74. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The firm has a market cap of $4.04 million, a P/E ratio of -0.96 and a beta of 1.25.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.